Advertisment ACS-IndiaSymposium
 
Journal of Pharmaceutical Negative Results
  Print this page Email this page Small font sizeDefault font sizeIncrease font size 
Search Article 
  
Advanced search 
 Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts  
 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 11  |  Issue : 1  |  Page : 47-53

Insignificant antidiabetic activities of ethanolic extracts of seeds of Archidendron pauciflorum


1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University; Department of Biotechnology, Faculty of Applied Science, AIMST University, Kedah, Malaysia
2 Department of Pharmaceutical Technology, Faculty of Pharmacy, AIMST University, Kedah, Malaysia
3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Kedah, Malaysia
4 Department of Pharmacology, Faculty of Pharmacy, AIMST University, Bedong, Kedah, Malaysia

Correspondence Address:
Dr. Sundram Karupiah
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling, Bedong, Kedah
Malaysia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpnr.JPNR_10_20

Rights and Permissions

Background: Archidendron pauciflorum (Fabaceae), commonly recognised as Dogfruit or Jering (Malaysia), is indigenous to Southeast Asia. The pounded leaves and bark of A. pauciflorum are used to treat gum pains, toothache, chest pains, skin ailments, and wounds. The antidiabetic effect of A. pauciflorum is not clear; hence, the present study is planned to evaluate the antidiabetic activities of ethanol extract of seeds of A. pauciflorum (ESAP) using both in vitro and in vivo models. Materials and Methods: Seeds of A. pauciflorum were sequentially extracted with hexane, chloroform, and ethanol, and the ethanolic extract was used in this study due to its various phytochemical constituents. Inhibitory activity of α-amylase and α-glucosidase (in vitro) was measured using the spectrophotometric method. For in vivo study, rats were used to induce diabetes mellitus (induced by streptozotocin) and ESAP was administered at the dose levels of 125, 250, and 500 mg/kg once daily through oral gavage for 21 consecutive days, and the antidiabetic effect of ESAP was compared with glibenclamide. Changes in glucose level and body weight were measured at regular intervals. Results: In vitro inhibition studies demonstrated that the ESAP had a moderate inhibitory activity for α-amylase and α-glucosidase. The rats treated with ESAP showed a significant decrease in their body weight at 21 days, whereas the glibenclamide treated rats showed a significant increase in their body weight. The standard drug glibenclamide was observed to significantly lower the blood glucose level, whereas the extract treated group did not show a significant change in levels of blood glucose when compared with control. Conclusion: The ESAP did not show any antidiabetic effect on diabetic rats.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed96    
    Printed4    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal